Page 205 - Drug Class Review
P. 205
Drug Effectiveness Review Project
donepezil placebo 65% 70% 9% 20% 4% 10% 2% 9% 0% 9% 2% 8% 0% 6% 0% 5% Significantly more donepezil patients experienced abnormal dreams (P = 0.03) Post randomization exclusions: No Overall loss to follow-up: 24% Loss to follow-up differential high: No placebo donepezil 19% 27% 9% 16% Page 133 of 205
ITT: Yes Method not reported Method not reported Yes Fair
Final Report Update 1 Authors: Seltzer et al. Year: 2004 ADVERSE EVENTS: Overall adverse effects reported: Diarrhea • Nausea • Asthenia • Abnormal Dreams • Dizziness • Injury • Insomnia • Significant differences in adverse events: ANALYSIS: ADEQUATE RANDOMIZATION: ADEQUATE ALLOCATION CONCEALMENT: BLINDING OF OUTCOME ASSESSORS: ATTRITION (overall): ATTRITION (treatment specific): Loss to follow-up: Withdrawals due to adverse events: QUALITY RATING: *primary outcome measures Alzheimer's Drugs